Person:
MAYADAĞLI, ALPASLAN

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ALPASLAN
Last Name
MAYADAĞLI
Name
Email Address
Birth Date

Filters

2013 - 201813
Reset filters

Settings

Author: AYDIN, TEOMAN ×

Search Results

Now showing 1 - 10 of 13
  • No Thumbnail Available
    PublicationMetadata only
    Thermal and Biochemical Effects of Low Level Electromagnetic Radiation on Rat Brains and Bodies
    (2014-06-01) KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLAN; GÜNEŞ BAYIR, AYŞE; YAGCI, B; TAŞPINAR, ÖZGÜR; AYDIN, TEOMAN; TRABZON, M; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; MAYADAĞLI, ALPASLAN; GÜNEŞ BAYIR, AYŞE; AYDIN, TEOMAN
  • No Thumbnail Available
    PublicationMetadata only
    Palliative Bioresonance Therapy for metastatic cancer patients Metastatik kanser hastalarında palyatif biyorezonans tedavisi
    (2018-02-01) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; BAYIR, AYŞE GÜNEŞ; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; SÜT, PELİN ALTINOK; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Low dose radiotherapy after the sonodynamic and photodynamic therapy with spirulina for relapsed cancer treatment: With literature review and three case reports
    (2018-08-01) KIZILTAN, HURİYE ŞENAY; ERIS, ALİ HİKMET; TEKÇE, ERTUĞRUL; AYDIN, TEOMAN; KABLAN, ÖZGÜR; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; TEKÇE, ERTUĞRUL; AYDIN, TEOMAN; KABLAN, ÖZGÜR; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Pain management with Radiotherapy and ozone with high dose vitamin C therapy in a case of bone metastatis of breast cancer patient
    (2018-02-01) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMAN; KIZILTAN, HURİYE ŞENAY; ERİŞ, ALİ HİKMET; GÜNEŞ BAYIR, AYŞE; BAŞIBÜYÜK, MERYEM; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; AYDOĞDU, İBRAHİM; ALTINOK SÜT, PELİN; AYDIN, TEOMAN
  • No Thumbnail Available
    PublicationMetadata only
    Metastatik kanser hastalarında palyatif biyorezonans tedavisi
    (2018-03-11) KIRSEVER, ESRA; KIZILTAN, HURİYE ŞENAY; YILMAZ, RABİYE; BAYIR, AYŞE GÜNEŞ; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; ŞİMŞEK, MUHARREM; KIZILTEPE, AYŞE; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; BAŞIBÜYÜK, MERYEM; ERİŞ, ALİ HİKMET; ÇAKIR, FATMA BETÜL; GÜL, KÜRŞAT; GÜMÜŞ, ASLI; KALAYCI, KÜBRA; AKÇAKAYA, ADEM; AYDIN, TEOMAN; AYDOĞDU, İBRAHİM; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Palyatif Bakım ve Hospis Sempozyum Kitapçığı
    (2013-08-01) Akçakaya, Adem; Güneş Bayır, Ayşe; Çakır, Fatma Betül; Hocaoglu, Ilknur Turk; Kızıltan, Huriye Şenay; Mayadağlı, Alpaslan; Seyithanoğlu, Hakan; Gül, Kürşat; Başıbüyük, Meryem; Şimşek, Muharrem; Aydın, Teoman; AKÇAKAYA, ADEM; ÇAKIR, FATMA BETÜL; KIZILTAN, HURİYE ŞENAY; MAYADAĞLI, ALPASLAN; GÜL, KÜRŞAT; BAŞIBÜYÜK, MERYEM; AYDIN, TEOMAN
  • Thumbnail Image
    PublicationOpen Access
    Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study
    (2014-01-01) Kiziltan, HURİYE ŞENAY; Bayir, Ayse Gunes; TAŞTEKİN, Didem; Coban, GANİME; Eris, ALİ HİKMET; Aydin, TEOMAN; MAYADAGLI, Alparslan; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ÇOBAN, GANİME; ERİŞ, ALİ HİKMET; AYDIN, TEOMAN; MAYADAĞLI, ALPASLAN
    Background: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at 6mg/m2 daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.
  • No Thumbnail Available
    PublicationMetadata only
    Medical ozone and radiotherapy in a peritoneal, erlich-ascites, tumor-cell model
    (2015-01-01) KIZILTAN, HURİYE ŞENAY; BAYIR, Ayşe Güneş; Yucesan, GÜL; Eris, ALİ HİKMET; KARATOPRAK, CUMALİ; İDİN, Kadir; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; YÜCESAN, GÜL; ERİŞ, ALİ HİKMET; KARATOPRAK, CUMALİ; AYDIN, TEOMAN; AKÇAKAYA, ADEM; MAYADAĞLI, ALPASLAN
  • No Thumbnail Available
    PublicationMetadata only
    Successfull Pain Management with Radiotherapy and Ozone Therapy in a Case of Metastatic, Chemotherapy Resistant Sino-Nasal Mucosal Malignant Melanoma
    (2017-03-01) KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; BAŞIBÜYÜK, MERYEM; MAYADAĞLI, ALPASLAN; AKÇAKAYA, ADEM; ÇAKIR, FATMA BETÜL; AYDIN, TEOMAN; GÜL, KÜRŞAT; KARABAL, ESRA; ŞİMŞEK, MUHARREM; KIZILTAN, HURİYE ŞENAY; GÜNEŞ BAYIR, AYŞE; ERİŞ, ALİ HİKMET; BAŞIBÜYÜK, MERYEM; MAYADAĞLI, ALPASLAN; AKÇAKAYA, ADEM; ÇAKIR, FATMA BETÜL; AYDIN, TEOMAN; GÜL, KÜRŞAT; KARABAL, ESRA
  • No Thumbnail Available
    PublicationMetadata only
    Clinical evaluation of simultaneous integrated boost in brain metastasis patients with helical intensity modulated radiotherapy
    (2018-04-01) KIZILTAN, HURİYE ŞENAY; ERIS, A.H.; MERAL, İSMAİL; SEYITHANOGLU, H.; DÜNDAR, TOLGA TURAN; EREN, F.; UNVER, NURCAN; AYDIN, TEOMAN; MAYADAĞLI, ALPASLAN; BAYIR, A.G.; CELIKTEN, M.; KIZILTAN, HURİYE ŞENAY; MERAL, İSMAİL; DÜNDAR, TOLGA TURAN; TEKÇE, ERTUĞRUL; ÜNVER, NURCAN; AYDIN, TEOMAN; MAYADAĞLI, ALPASLAN
    Background: This study was performed to assess patient survival and treatment toxicity after helical tomotherapy (HT) with simultaneous integrated boost (SIB) radiotherapy (RT) for cancer patients with one to eight brain metastases (BM) who have been treated with or without surgery. Materials and Methods: A total of 48 brain metastasis (BM) patients were included in this retrospective study between April 2015 and December 2016,. The patients were treated with image-guided intensity modulated radiation therapy (IMRT) on the helical tomotherapy (HT) machine. Whole brain HT as 25 Gy and SIB to metastasis sites as 35 Gy was delivered in 10 fractions. The patient were aged between 50 to 80 years old, volume of the BM was between 6 to 75 cc and the number of brain metastasis was between 1 to 8, Karnofsky Performance Score (KPS) ranged between 50-90 and RPA I-III. Surgery was performed to two patients before RT. The maximum patient follow-up time was 20 months. Results: The primary neurotoxicity observed in patients was grade I- II brain edema related headache and lethargy. In patients who had survived 3- 12 months, KPS improved median score of 20 points and RPA was grade I after six months. Twelve patients had passed away at the end of a 20- month follow-up. Conclusion: HT utilizing SIB treatment for 1- 8 BM was achieved successfully with no significant toxicity. An improvement of performance status indicators of patients following RT was observed.